RELATED PARTY TRANSACTIONS |
3 Months Ended | |
|---|---|---|
Mar. 31, 2016 | ||
| Related Party Transactions [Abstract] | ||
| Related Party Transactions Disclosure [Text Block] |
9. RELATED PARTY TRANSACTIONS
The Company’s Chief Scientific Officer and principal founder of Cellectar, who is a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”). During the three months ended March 31, 2016, the Company incurred approximately $71,000 in expenses from UW for costs associated with clinical trial agreements. The Company had accrued liabilities to UW of approximately $128,000 as of March 31, 2016.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|